Differential down-regulation of alpha-2 adrenergic receptor subtypes

Life Sciences

Volumn 62, Issue 17-18, 1998, Pages 1467-1472

  Heck, Donald A ^a   Bylund, David B ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Alpha 2 adrenergic receptor; Degradation; Down regulation; G protein; Regulation; Subtype

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; CELL SURFACE RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; RECEPTOR SUBTYPE;

ANIMAL CELL; CHO CELL; CONFERENCE PAPER; INTERNALIZATION; LIGAND BINDING; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RECEPTOR BINDING; RECEPTOR DENSITY; RECEPTOR DOWN REGULATION; TRANSCRIPTION REGULATION;

ANIMALS; CHO CELLS; CRICETINAE; DOWN-REGULATION; GTP-BINDING PROTEINS; HT29 CELLS; HUMANS; RECEPTORS, ADRENERGIC, ALPHA-2;

EID: 0032571351     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(98)00091-5     Document Type: Conference Paper

References (31)

1. 1. M.L. TOEWS, P.E. SHREVE and D.B. BYLUND, Signaling Mechanisms in Secretory and Immune Cells, J.R. Martinez, B.S. Edwards and J.C. Seagrave (eds), 1-17, San Francisco Press, San Francisco (1991).
2. 2. L. HEIN and B.K. KOBILKA, Neuropharmacology 34 357-366 (1995).
3. 3. R.C. PLEUS, P.E. SHREVE, M.L. TOEWS and D.B. BYLUND, Eur.J.Pharmacol. 244 181-185 (1993).
4. 4. D.R. CERUTIS, J.D. DEUPREE, D.A. HECK, S.-J. ZHU, M.L. TOEWS and D.B. BYLUND, Alpha-2 Adrenergic Receptors: Structure, Function and Therapeutic Implications, S. Lanier and L.E. Limbird (eds), 103-112, Gorden and Breach, London (1996).
5. 5. D.K. BERG and Z.W. HALL, Science 184 473-475 (1974).
6. 6. P.N. DEVREOTES and D.M. FAMBROUGH, J.Cell Biol. 65 335-358 (1975).
7. 7. P.N. DEVREOTES, J.M. GARDNER and D.M. FAMBROUGH, Cell 10 365-373 (1977).
8. 8. K.A. NEVE and P.B. MOLINOFF, Mol.Pharm. 30 104-111 (1986).
9. 9. M.D. SNAVELY, M.G. ZIEGLER and P.A. INSEL, Mol.Pharmacol. 27 19-26 (1985).
10. 10. H.-Y. WANG, J.-F. LIAO and C.C. MALBON, Chinese J.Physiol. 39 83-93 (1996).
11. 11. D.A. HECK and D.B. BYLUND, J.Pharmacol.Exp.Ther. in press (1997).
12. 12. N.J. IZZO and W.S. COLUCCI, Am.J.PPhysiol. 266 C771-C775 (1994).
13. 13. K. HOSODA, G.K. FEUSSNER, L. RYDELEK-FITZGERALD, P.H. FISHMAN and R.S. DUMAN, J.Neurochem. 63 1635-1645 (1994)
14. 14. K. HOSODA, L.R. FITZGERALD, V.A. VAIDYA, G.K. FEUSSNER, P.H. FISHMAN and R.S. DUMAN, Mol.Pharmacol. 48 206-211 (1995).
15. 15. F. BARTUREN and J.A. GARCIA-SEVILLA, Molecular Pharmacology 42 846-855 (1992).
16. 16. C. RIBAS, A. MIRALLES and J.A. GARCILLA-SEVILLA, Br.J.Pharmacol. 110 99-106 (1993).
17. 17. P.E. SHREVE, M.L. TOEWS and D.B. BYLUND, Eur.J.Pharmacol. 207 275-276 (1991).
18. 18. S. ULLRICH and C.B. WOOLHEIM, J.Biol.Chem. 259 4111-4115 (1984).
19. 19. C.M. FRASER, S. ARAKAWA, W.R. MCCOMBIE and J.C. VENTER, J.Biol.Chem. 264 11754-11761 (1989).
20. 20. S.B. JONES and D.B. BYLUND, Biochem.Pharmacol.40 871-877 (1990).
21. 21. M.G. EASON and S.B. LIGGETT, J.Biol.Chem. 267 25473-25479 (1992).
22. 22. E. DUZIC, I. COUPRY, S DOWNING and S.M. LANIER, J.Biol.Chem. 267 9844-9851 (1992).
23. 23. M.G. EASON, M.T. JACINTO, C.T. THEISS and S B. LIGGETT, Proc.Natl.Acad.Sci.USA 91 11178-11182 (1994).
24. 24. A.D. FEDERMAN, B.R. CONKLIN, K.A. SCHRADER, R.R. REED and H.R. BOURNE, Nature 356 159-161 (1992).
25. 25. J. NASMAN, C.C. JANSSON and K.E.O. AKERMAN, J.Biol.Chem. 272 9703-9708 (1997).
26. 26. H. KUROSE and R.J. LEFKOWITZ, J.Biol.Chem. 269 10093-10099 (1994).
27. 27. R. SCHULEIN, U. LIEBENHOFF, H. MULLER, M. BIRNBAUMER and W. ROSENTHAL, Biochem.J. 313 611-616 (1996).
28. 28. E.A. JEWELL-MOTZ, E.T. DONNELLY, M.G. EASON and S.B. LIGGETT, Biochemistry 36 8858-8863 (1997).
29. 29. M.J. LOHSE, Biochim.Biophys.Acta 1179 171-188 (1993).
30. 30. J.M. THOMAS and B.B. HOFFMAN, Endocrinology 119 1305-1314 (1986).
31. 31. D.B. BYLUND, N.A. HASS, D.R. CERUTIS and H.S. BLAXALL, Pharmacol.Commun. 6 87-90 (1995).